Get the Stockscreener App
5.98
3.46%
0.20
After Hours:
6.04
0.06
+1.00%
Vir Biotechnology Inc stock is traded at $5.98, with a volume of 1.41M.
It is up +3.46% in the last 24 hours and up +13.69% over the past month.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
See More
Previous Close:
$5.78
Open:
$5.85
24h Volume:
1.41M
Relative Volume:
1.04
Market Cap:
$830.72M
Revenue:
$62.04M
Net Income/Loss:
$-533.34M
P/E Ratio:
-1.5255
EPS:
-3.92
Net Cash Flow:
$-473.07M
1W Performance:
+3.46%
1M Performance:
+13.69%
6M Performance:
-4.93%
1Y Performance:
-18.64%
1-Day Range:
$5.81
$6.025
1-Week Range:
$5.745
$6.44
52-Week Range:
$4.155
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology Inc
Sector
Industry
Phone
415-906-4324
Address
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.98 | 802.94M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Evercore ISI | Outperform |
| Aug-27-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-29-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-23 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Feb-21-23 | Upgrade | Goldman | Neutral → Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-14-22 | Initiated | SVB Leerink | Outperform |
| Sep-09-22 | Initiated | Morgan Stanley | Underweight |
| Mar-03-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Dec-21-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Oct-25-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Jan-27-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-20-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Sep-14-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-11-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-20-20 | Initiated | Needham | Buy |
| Mar-19-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-13-20 | Downgrade | Goldman | Buy → Neutral |
| Feb-27-20 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Feb-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-19 | Initiated | Robert W. Baird | Neutral |
| Nov-05-19 | Initiated | Barclays | Overweight |
| Nov-05-19 | Initiated | Cowen | Outperform |
| Nov-05-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | JP Morgan | Overweight |
View All
Vir Biotechnology Inc Stock (VIR) Latest News
What the charts say about Vir Biotechnology Inc. todayJuly 2025 Highlights & AI Driven Price Predictions - newser.com
Is now a turning point for Vir Biotechnology Inc.July 2025 Drop Watch & Weekly Watchlist for Consistent Profits - newser.com
How Vir Biotechnology Inc. stock reacts to inflationary pressuresJuly 2025 Pullbacks & Low Drawdown Investment Strategies - newser.com
Visualizing Vir Biotechnology Inc. stock with heatmaps2025 Major Catalysts & Fast Entry and Exit Trade Plans - newser.com
Pattern recognition hints at Vir Biotechnology Inc. upsideWeekly Gains Report & AI Powered Market Trend Analysis - newser.com
Risk adjusted return profile for Vir Biotechnology Inc. analyzed2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
Will Vir Biotechnology Inc. stock deliver consistent dividendsJuly 2025 Final Week & Pattern Based Trade Signal System - newser.com
Why Vir Biotechnology Inc. stock remains on watchlists2025 Big Picture & Real-Time Price Movement Reports - newser.com
How to escape a deep drawdown in Vir Biotechnology Inc.Oil Prices & Weekly Watchlist for Consistent Profits - newser.com
What high frequency data says about Vir Biotechnology Inc.July 2025 Pullbacks & Low Risk High Reward Ideas - newser.com
Is Vir Biotechnology Inc. forming a reversal patternNew Guidance & Real-Time Market Trend Scan - newser.com
Vir Biotechnology Inc Stock (VIR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):